<SEC-DOCUMENT>0001193125-23-276668.txt : 20231114
<SEC-HEADER>0001193125-23-276668.hdr.sgml : 20231114
<ACCEPTANCE-DATETIME>20231114074925
ACCESSION NUMBER:		0001193125-23-276668
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20231114
FILED AS OF DATE:		20231114
DATE AS OF CHANGE:		20231114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		231401619

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d344354d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of November, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2023, Kazia Therapeutics Limited (the &#147;Company&#148;) issued a press release titled, &#147;Kazia Announces
Publication in Molecular Cancer Therapeutics Highlighting Paxalisib Preclinical Data in Melanoma,&#148; regarding the publication of data stemming from the Company&#146;s research collaboration with the Huntsman Cancer Institute at the University of
Utah. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The paper has been published online in Molecular Cancer Therapeutics, and reviews paxalisib&#146;s activity <I>in vitro</I> and
<I>in vivo</I> against preclinical models of metastatic melanoma. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Points from the Publication </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Activation of the PI3K / Akt / mTOR pathway, which is the target of paxalisib, is common in melanoma and has been
identified as a key resistance mechanism to some established therapies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>In vitro</I>: Treatment with paxalisib was observed to lead to a significant decrease in melanoma cell growth
in multiple cell lines and was also observed to inhibit downstream signaling through the PI3K/AKT cascade, leading to its negative effect on melanoma cell growth. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>In vivo</I>: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mice bearing tumors who were dosed with 15 mg/kg paxalisib daily; paxalisib was observed to inhibit of tumor
growth and significantly extended the overall survival of these mice (p=0.0003) compared to vehicle </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In a MTG004 patient derived xenograft mouse model that is resistant to dabrafenib and trametinib (inhibitors of
mutant BRAF and MEK, respectively). At day 21, the mean tumor volume in the paxalisib treated mice was observed to be significantly lower than vehicle (P = .05) or dabrafenib/trametinib treated mice (P = .01) </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by reference the information contained herein, excluding Exhibit 99.1, into the Company&#146;s registration
statement on Form <FONT STYLE="white-space:nowrap">F-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-259224).</FONT> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d344354dex991.htm">Press Release of Kazia Therapeutics Limited dated November&nbsp;10, 2023 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Kazia Therapeutics Limited</B> (Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Karen Krumeich</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Karen Krumeich</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date:
14&nbsp;November 2023 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d344354dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g344354g1114014349146.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PRESS RELEASE </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10&nbsp;November 2023 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KAZIA ANNOUNCES
PUBLICATION IN MOLECULAR </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRECLINICAL DATA IN MELANOMA </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sydney,
10</B><B></B><B>&nbsp;November 2023</B> &#150; Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the publication in Molecular Cancer Therapeutics highlighting paxalisib
preclinical data stemming from the research collaboration with the Huntsman Cancer Institute at the University of Utah in Salt Lake City, UT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The paper
by Dr Gennie Parkman and colleagues, working in the laboratory of Professor Sheri Holmen, has shown paxalisib to be active <I>in vitro</I> and <I>in vivo</I> against preclinical models of metastatic melanoma, the most aggressive form of skin cancer.
Dr Parkman&#146;s data highlights paxalisib as a dual inhibitor of both the PI3K and MTOR pathways and cites in the manuscript that paxalisib, &#147;may represent a promising therapeutic strategy in this disease in both the first line and MAPK
inhibitor resistant setting&#148; for BRAF-mutant cutaneous melanoma. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>&#147;This is promising data for paxalisib, which reinforces its potential for
use in an area outside of our traditional brain cancer areas of focus,&#148; commented Dr John Friend, Kazia&#146;s CEO. &#147;We are privileged to be working with one of the world&#146;s leading melanoma centers on this outstanding research project
and hope it may lead to a new way of treating melanoma for patients without suitable therapies.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Points from the Publication </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Activation of the PI3K / Akt / mTOR pathway, which is the target of paxalisib, is common in melanoma and has been
identified as a key resistance mechanism to some established therapies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>In vitro</I>: Treatment with paxalisib was observed to lead to a significant decrease in melanoma cell growth
in multiple cell lines and was also observed to inhibit downstream signaling through the PI3K/AKT cascade, leading to its negative effect on melanoma cell growth. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>In vivo</I>: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mice bearing tumors who were dosed with 15 mg/kg paxalisib daily; paxalisib was observed to inhibit of tumor
growth and significantly extended the overall survival of these mice (p=0.0003) compared to vehicle </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In a MTG004 patient derived xenograft mouse model that is resistant to dabrafenib and trametinib (inhibitors of
mutant BRAF and MEK, respectively). At day 21, the mean tumor volume in the paxalisib treated mice was observed to be significantly lower than vehicle (P = .05) or dabrafenib/trametinib treated mice (P = .01) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The authors concluded: &#147;<I>Our results support the use of paxalisib as a single agent either in the first
line or MAPK inhibitor resistant setting for BRAF-mutant cutaneous melanoma. In this paper, we demonstrate the beneficial use of next generation PI3K/mTOR inhibitors, notably paxalisib, to inhibit melanoma cell growth.&#148;</I><I></I>
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The paper has been published online in Molecular Cancer Therapeutics and can be accessed at the following
website: <U>https://pubmed.ncbi.nlm.nih.gov/37931033/</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Melanoma </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximately 1 in 50 people will be diagnosed with melanoma during their lifetime. Most cases are localized to the skin and can be cured through surgical
resection. However, about 20% of cases spread (metastasis) and require more complex and ongoing treatment.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Melanoma represents
approximately 1% of all skin cancers, but accounts for the majority of deaths from skin cancer. For melanoma that is confined to the skin at the time of diagnosis, the five-year survival rate is 99.5%. However, for melanoma that has spread to
distant sites (metastatic melanoma), the five-year survival rate falls to 32%.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximately 50% of patients harbor activating
mutations in the BRAF gene. Such patients are typically treated with the combination of a BRAF inhibitor and a MEK inhibitor. The introduction of targeted therapies has improved the average survival of patients with BRAF-mutant metastatic melanoma
from approximately 6 months to approximately 24 months. However, we believe there remains a need for additional therapeutic options to further improve survival. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Next Steps </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia anticipates further data from the
ongoing collaboration with the Huntsman Cancer Institute in CY2024. Depending on the results, Kazia may evaluate future opportunities to launch a clinical trial of paxalisib in melanoma. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorized for release by Dr.&nbsp;John Friend, CEO. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics
Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is paxalisib, a
brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A
completed Phase 2 study in glioblastoma reported promising signals of clinical activity in 2021, and a pivotal study, GBM AGILE, is ongoing, with final data expected in CY2023. Other clinical trials are ongoing in brain metastases, diffuse midline
gliomas, and primary CNS lymphoma, with several of these having reported encouraging interim data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paxalisib was granted Orphan Drug Designation for
glioblastoma by the US Food and Drug Administration (US FDA) in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by
the US FDA for DIPG in August 2020, and for atypical teratoid / rhabdoid tumours (AT/RT) in June 2022 and July 2022, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia is also
developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided evidence of synergy with immuno-oncology
agents. A Phase 1 study in advanced solid tumors commenced recruitment in November 2021. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit <U>www.kaziatherapeutics.com</U> or follow us on Twitter @KaziaTx. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement may contain
forward-looking statements, which can generally be identified as such by the use of words such as &#147;may,&#148; &#147;will,&#148; &#147;estimate,&#148; &#147;future,&#148; &#147;forward,&#148; &#147;anticipate,&#148; or other similar words. Any
statement describing Kazia&#146;s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements
regarding: the timing for results and data related to Kazia&#146;s clinical and preclinical trials, and Kazia&#146;s strategy and plans with respect to its programs, including paxalisib and EVT801, as well as any potential future indications for
such programs. Such statements are based on Kazia&#146;s current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ
materially from those anticipated in the forward-looking statements, including risks and uncertainties: associated with clinical and preclinical trials and product development, related to regulatory approvals, and related to the impact of global
economic conditions. These and other risks and uncertainties are described more fully in Kazia&#146;s Annual Report, filed on form <FONT STYLE="white-space:nowrap">20-F</FONT> with the SEC, and in subsequent filings with the United States Securities
and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue
reliance on these forward-looking statements, which apply only as of the date of this announcement. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g344354g1114014349146.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g344354g1114014349146.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !X Q<# 2(  A$! Q$!_\0
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M)#M /48]#Z4)<W$801W$R"-MR!9"-I]1Z&GRZ6%S:W.TM)==TKX?RONU&?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRJG<D8'X5Y]5O4]2NM7U&:_O9#)/,VYCZ>P]A52M8II:F3:;T"NZTSX?/?\
MP^N==_>"]!,D$8/!C'7CU/6N6T'2)==URTTV(',S@,?1>Y_*OIF!K"Q^S:.K
MQJ_D_NX?5!P>*BI*VQ4(WW/E6BNC\<Z ?#OBFZM54BWD/FP'_9/;\.E<Y6B=
MU<AJSL=U\.?!VF^+7OQJ,ERHM]NSR7"]<]<@UWO_  IKPS_SVU+_ +_K_P#$
MUX4DLD63'*\>>I1RO\J]U^%^C/I'AJ36-1ED\VZ7S,RN3Y<0Z=?SK.I=:W-(
M6>ECAOB)X2T'PG#:1:?-=O>SDL5ED# (._0=ZX&MOQ9KS^(_$EUJ#$^66V0J
M?X4'2L2KC>VI$K7T/3? 'P^T?Q1X>:_OY+Q9A,R8AD"C _ UYQ=Q+!>3PJ25
MCD903UP#7N7P=_Y$QO\ KY>O$-1_Y"EW_P!=G_F:F+?,RI)<J*U6]+T^?5M5
MM=/MQF6XD"#CIZG\!DU4KU;X-^'_ #;FYUZ=/ECS!;Y'?^(_R'YU4G97)BKN
MQS'Q \'IX3U2W6U,C65Q'E&<Y(<?>&?R/XUR%?1/C33+;QCX+N&L'2>2$F6W
M=.[ID,OX\BOG:IA*ZU'.-GH%%%%60%%%% !1110 4444 %%%% !3HT\R5$!P
M68+GZTVGPL$GC=ONJX)_.@9HZIH<VDEEGF1I3</#%&JG=(JD@N/1<\#UY]*I
MII][)*\265R\D8RZ+"Q91ZD8R*Z34=?TO5-=BU2Y-P)8;LC<BD&6WR2AX/#+
MTQW'N*<=<T_[:MU'J$D%S#8K!%(MNZIYFYLMM!)X!XSW^E*['9',_9)6$0@2
M:9G0NRK"WRX)'XCCJ*LZ+ID.KZ@EG)?"TDD.(RT+2!CZ<=*V]+UW3;:*Q$TL
MRR6\2H6\IG4XF+D8!&201@G@&LK3M1MK7Q6NHR;Q;"Y>7A<G:22./QHU"R(F
MTDR6MQ=6,S7<,,JQY2!E9L@G..< ;:H"&8P^<(9#%G;YFP[<^F>F:VM#UB#3
M;=$DDE0_;H9VV \HH;/\QQ5MM?LSHBVRDI($,100$E@9=^=V[ &/;.11=A9'
M/&RNPQ4VEP&"[B/*;(7UZ=/>F?9Y_(\_R)?)_P">FP[?SZ5UEGXDL%UV^O[F
M>X(ENEDC+HTF8QGC;N&#TQG.*BGU"WM_#MJK3R.TUK-&EL%^7F7(8G.!C'I1
M=A9',FVN!LS;S#>-R9C/S#U'J*EATV]GMYKB*UF:&%0\CA#A5)P#743^)]/E
MOK>4.XB,C.ZI;D&+,>SJ6.X^PP,50GU:P:SFM([F;:;*&%9/*(#.C[B,9X!'
M>B["R,22TD$LJPI-,D8!9Q"PP,=2.WXU$T,R0K,T,BQ-]URA"M]#T-=+/KEE
M<&YV7EW:DRK*C1)\TH$>S:>>.?6JFH:I:W6@0VPGFDNE"+C84 "YX;G:V.Q
M!]:+L+(H7&FM:W%I%),"+B)90R(6*AL\8ZD\=JA%C=OS':W#H20K+"V#^E;C
M7^EFZTF_%])YMK''');_ &9L_*3DALX/6IU\26Z6PB6>Y7$6W"@@9\[?Z^E%
MV%D8-MI5U>QYM(9II &9T6(_*J]3GH?I54PS"(2F&01$[0Y0[<^F>F:Z==?L
M2\BF69%DDN3N$9^42#Y3C/YT)XBLX])M8>LD21QO$(2=VU]V[<6P/P&:+L+(
MP;G39[2PM[J8,GGNRB-T*L,=^>QJG6YKFI6MY:00P74]PR3RRLTJ%=H<Y &2
M>E8=-"84444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 5
M5+,%'4G KI+[1=2TO1&8:@S0\&6!20!G^=<T"0<@X(KI95\0ZKH8=S&UL!G
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M@9H?V#?"[T^V*Q"2_56AR_'/]X]CT_,4]/#M]-<)#;O;3^9"\\<D4N4=4X8
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M<&KZ7VF3>)9=0FE=(U4/&S0E@\H4#)4'(7/./PI]MKBPZ?+%+?2SN&<QI]G
MPY8$2ACSGC.#1=A9&5-I=S;W,<$S01F3.V0S+Y?!P<MT&#Q4\GA^]A\\RR6<
M:P!"SM<J%.X97![DBK6L:G8ZA<:?&K?N(69I9$M_+SN8$_+D\\<^YJ:UU^(:
ME?3RW#QVTTP?[/Y <2HO 4D_=XQ1=A9&(]A<QZ=%?N@%O+(8T;<,DCD\=<>]
M5JV]0U>RO-!M[.*TDAGAD!'[W<FT \@8ZY-8E-"84444""BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
